Abingdon Healt. Regulatory News (ABDX)

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Abingdon Health plc

("Abingdon Health" or "the Company")

Funding award to develop test for malaria parasite

Point-of-care rapid diagnostic test for Plasmodium vivax infection to be developed for in-field testing

York, U.K. 27 January 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces that it has been awarded approximately £800,000 as part of total project funding of EUR 5m to develop, and transfer to manufacture, a new intervention for malaria elimination as part of a distinguished group of Institut Pasteur (and its affiliates in Madagascar and Senegal), the Armauer Hansen Research Institute in Ethiopia, FIND, London School of Hygiene & Tropical Medicine (LSHTM) and Walter and Eliza Hall Institute of Medical Research (WEHI). The project is scheduled to begin in February 2025 and be delivered over 24 months.

The funding to Abingdon Health, which will be provided by UK Research and Innovation (UKRI) under the 'Horizon Europe Guarantee' scheme, is to allow the Company to lead the development of a point-of-care (POC) rapid diagnostic test (RDT) for Plasmodium vivax (P.vivax) infection to support in-field testing and treatment to facilitate malaria control strategy.

The primary purpose of the PvSeroRDT (P. vivax Serological Rapid Detection Test) project is to develop a POC RDT for field-based implementation that replicates lab-based tests for the detection of P. vivax. Once the RDT has successfully been developed, Abingdon Health will transfer the product to diaTROPIX, a Senegalese manufacturing organisation based at Institut Pasteur Dakar. Establishing African-based manufacturing is important in helping to build new infrastructure, aiming to facilitate the preparation, management, and response to infectious diseases. Abingdon Health is committed to ensuring the support of the scaling up, transfer to manufacturing and support to diaTROPIX, to ensure they are well equipped to deliver PvSeroRDT's to African communities, particularly those in sub-Saharan Africa.

The PvSeroRDT project will contribute a robust POC diagnostic to the pipeline in sub-Saharan Africa. The project is designed to address the World Health Organisation's preferred product characteristic for P. vivax diagnosis, to translate from an SME prototype to African-based industrial design, to test clinical performance in several African sites, and to facilitate field deployment. This will ultimately secure healthcare provider access to this novel diagnostic, facilitating implementation of P. vivax serological testing and treatment - a new intervention for malaria elimination.

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to have won this grant award as part of a world-leading group of institutions. We are excited to add Abingdon Health's RDT development and manufacturing scale-up expertise to that of our distinguished group of partners. Working with the Institut Pasteur, FIND, LSHTM, and WEHI gives us a great opportunity to produce rapid tests to aid the management of malaria."

Dr Michael White, Director of Research at Institute Pasteur commented: "We are very pleased to partner with Abingdon Health to develop and manufacture a new rapid diagnostic test for Plasmodium vivax malaria that is poised to make an important contribution to malaria elimination efforts."

The person responsible for arranging the release of this announcement on behalf of the Company is Chris Hand, Executive Chairman of the Company.

Enquiries

About Abingdon Health plc

Abingdon Health is a leading med-tech contract service provider offering its services to an international customer base.

The Group's CDMO division offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".

Abingdon Health's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon Health's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com